|
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)
|
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
| Operating expenses: | ||
| Research and development | $ 321,439us-gaap_ResearchAndDevelopmentExpense | $ 217,868us-gaap_ResearchAndDevelopmentExpense |
| General and administrative | 782,846us-gaap_GeneralAndAdministrativeExpense | 656,216us-gaap_GeneralAndAdministrativeExpense |
| Total operating expenses | 1,104,285us-gaap_OperatingExpenses | 874,084us-gaap_OperatingExpenses |
| Other income (expense), net: | ||
| Research & development tax credit | 0eyeg_ResearchAndDevelopmentTaxCredit | 2,940eyeg_ResearchAndDevelopmentTaxCredit |
| Interest income | 164us-gaap_InvestmentIncomeInterest | 307us-gaap_InvestmentIncomeInterest |
| Interest expense | (1,920,146)us-gaap_InterestExpense | (32,055)us-gaap_InterestExpense |
| Change in warrant liability | 223,172us-gaap_FairValueAdjustmentOfWarrants | 0us-gaap_FairValueAdjustmentOfWarrants |
| Other income (expense), net | 10us-gaap_OtherNonoperatingIncomeExpense | 0us-gaap_OtherNonoperatingIncomeExpense |
| Total other expense, net | (1,696,801)us-gaap_NonoperatingIncomeExpense | (28,808)us-gaap_NonoperatingIncomeExpense |
| Net Loss | (2,801,086)us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple | (902,892)us-gaap_IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple |
| Deemed dividend on preferred stock | (8,222,008)us-gaap_PreferredStockDividendsAndOtherAdjustments | 0us-gaap_PreferredStockDividendsAndOtherAdjustments |
| Net income attributable to non-controlling interests | (5,177)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest | (58,948)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
| Net (loss) attributable to Eyegate Pharmaceuticals, Inc. stockholders | (11,028,271)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic | (961,840)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
| Net loss per common share - basic and diluted | $ (3.23)us-gaap_EarningsPerShareBasicAndDiluted | $ (0.47)us-gaap_EarningsPerShareBasicAndDiluted |
| Weighted average shares outstanding - basic and diluted | 3,417,509us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted | 2,025,527us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
| Net loss | (2,801,086)us-gaap_ProfitLoss | (902,892)us-gaap_ProfitLoss |
| Other comprehensive income (loss): | ||
| Foreign currency translation adjustments | 51,325us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax | 8,994us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax |
| Comprehensive income (loss) | (2,749,761)us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest | (911,886)us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest |
| Less: | ||
| Net income attributable to non-controlling interests | (5,177)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest | (58,948)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
| Other comprehensive (income) loss attributable to non-controlling interests | 32,967us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest | (6,819)us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest |
| Comprehensive income attributable to non-controlling interests | 27,790us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest | (65,767)us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest |
| Comprehensive loss attributable to Eyegate Pharmaceuticals, Inc. stockholders | $ (2,721,971)us-gaap_ComprehensiveIncomeNetOfTax | $ (959,665)us-gaap_ComprehensiveIncomeNetOfTax |
| X | ||||||||||
|
- Definition
This element represents that, the amount of research and development tax credit. No definition available.
|
| X | ||||||||||
|
- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
|
- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Income or Loss from continuing operations, net of taxes, including net Income or Loss from discontinued operations but before extraordinary items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|